


10/ Pre B
c/m
8-27-02

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231, ON THE DATE INDICATED BELOW.

BY: Hickie Jones

DATE: 8/27/02



PATENT Ref
BOX RCE 9-13-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

SEP 09 2002

TECH CENTER 1600/2900

In Re: Patent Application of : Group Art Unit: 1615
Lisbeth ILLUM *et al.* :
: Conf. No.: 2569 :
: Appln. No.: 09/834,312 : Examiner: B. Fubara
: Filed: April 13, 2001 :
: For: NOVEL FORMULATIONS OF : Attorney Docket
FEXOFENADINE : No. 10774-56US
: (WESX/P21598US)

AMENDMENT AFTER FINAL

In response to the Office Action mailed March 27, 2002 (Paper No. 7), please consider the following amendments and remarks. This response is timely filed on August 27, 2002, in view of the Petition for a two month extension of time up to and including August 27, 2002. This Amendment is filed with a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114.

Kindly amend the application as follows:

In the Claims:

Please amend claim 1 to read as follows:

B1

1. (Amended) A composition consisting essentially of (i) fexofenadine or a pharmaceutically acceptable salt thereof and (ii) a pharmaceutical excipient which increases the solubility of the fexofenadine or salt in water, which is adapted for delivery of the fexofenadine or pharmaceutically acceptable salt thereof to the eye or nose.

33
Please add new claims 23-32 as follows:

B2

23. (New) A composition comprising (i) fexofenadine or a pharmaceutically